Myocardial bridge in coronary arteries. Malformation of coronary vessels
Conditions
Interventions
Intervention 1: Intervention group: For the intervention group, in addition to beta-blocker Bisoprolol Fumarate (Concor) Tablet 2.5 mg daily (Brand: Abidi), Ranolazine Tablet 500 mg daily (Xinaro 500m
Sponsors
Shiraz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Iranian origin No history of organ damage, heart failure or renal failure Willingness to participate in research Angina or dyspnea on exertion or at rest No coronary artery disease (less than 50% stenosis in all epicardial coronary arteries)
Exclusion criteria
Exclusion criteria: Not willing to keep participating in the trial patients younger than 18 years Liver failure, long QT, renal failure Using CYP3A inhibitors such as Diltiazem, Verapamil, Ketoconazole, Macrolides and protease inhibitors Patient who are using medication that cause QT prolongation Pregnancy or lactation Parkinson's disease Life expectancy less than 6 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity of chest pain. Timepoint: At the beginning- 6 month later. Method of measurement: Seattle Angina Questionnaire (SAQ) and The Duke Activity Status Index (DASI). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactYaser Rahbarian
Shiraz University of Medical Sciences
Outcome results
None listed